
- Oncology NEWS International Vol 12 No 2
- Volume 12
- Issue 2
Task Force Does Not Recommend Routine Prostate Cancer Screening
ROCKVILLE, Maryland-The US Preventive Services Task Force has concluded that not enough scientific evidence exists to promote routine screening of all men over age 40 for prostate cancer via standard PSA test and/or digital rectal exam. The task force-sponsored by the Agency for Healthcare Research and Quality-concluded that the tests are effective for diagnosis but that there is insufficient evidence to show that they affect long-term health or survival. The task force noted that results of the ongoing Prostate, Colorectal, Lung, and Ovarian Screening Trial, designed to answer this question, will not become available until later in this decade.
ROCKVILLE, MarylandThe US Preventive Services Task Force has concluded that not enough scientific evidence exists to promote routine screening of all men over age 40 for prostate cancer via standard PSA test and/or digital rectal exam. The task forcesponsored by the Agency for Healthcare Research and Qualityconcluded that the tests are effective for diagnosis but that there is insufficient evidence to show that they affect long-term health or survival. The task force noted that results of the ongoing Prostate, Colorectal, Lung, and Ovarian Screening Trial, designed to answer this question, will not become available until later in this decade.
If physicians opt to perform the two tests, the task force recommends that they first discuss the uncertain benefits and potential harm of such screening with their patients. The task force report is available online at
Articles in this issue
over 22 years ago
Some Activity for Gefitinib in Heavily Pretreated Breast Cancerover 22 years ago
Brachytherapy Results Similar for Blacks, Whitesover 22 years ago
Dose-Dense Chemo Ups Survival in Node+ Breast Cancerover 22 years ago
MR Spectroscopy IDs Breast Cancers, Node Involvementover 22 years ago
ODAC Wants More Data on Expanded Casodex Indicationover 22 years ago
SuperGen Submits First NDA Module for Pancreatic Cancer Drugover 22 years ago
Two Added to ONI’s Oncology Nursing Editorial Advisory Boardover 22 years ago
Bortezomib Active in Relapsed/Refractory Myelomaover 22 years ago
Telomerase Potential Cancer BiomarkerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.